NEW YORK, June 25, 2015 /PRNewswire/ -- The prestigious Fierce 15 biotech award has come to symbolize novelty and being at the forefront of biotechnology development amongst privately held businesses. The winners of this award are aiming at breakthroughs and big things, not at being 'me-too'.
This unique product, the 'Fierce 15 in Oncology Drug Pipeline Update' gathers the last five years (2010-2014) of Fierce 15 awards and identifies that no less than 45 of these biotech companies who are developing cancer drugs. This is a solid 60% of all companies given the award.
Fierce 15 companies are fast movers and to date no less than eleven out of the 45 companies are public companies and four have been acquired, namely Amira Pharmaceuticals, Aragon Pharmaceuticals, Avila Therapeutics and Plexxikon.
FibroGen is the oldest among them, founded in 1993, otherwise all others are from the beginning of 2000 to present day. Among the very latest of the start-ups you will find Jounce Therapeutics, Juno Therapeutics and Navitor Pharmaceuticals.
Available for the first time, Fierce 15 in Oncology lets you perform detailed pipeline analysis on their collective and very impressive pipeline of more than 180 drugs, spanning from Discovery to Marketed. Thirteen drugs have one or more orphan drug designations and one drug has received breakthrough therapy designation. Key technologies among this group of companies include CAR-T, TCRs, Immuno-oncology, Immune checkpoints, Antibodies etc.
There are today 46 companies plus partners developing 122 Fierce 15 drugs in 326 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 30 drugs. Fierce 15 In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 94 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 87 out of the 90 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 37 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
How May Drug Pipeline Update Be of Use?
* Show investors/board/management that you are right on top of drug development progress in your therapeutic area. * Find competitors, collaborations partners, M&A candidates etc. * Jump start competitive drug intelligence operations * Excellent starting point for world wide benchmarking * Compare portfolio and therapy focus with your peers * Speed up pro-active in-/out licensing strategy work * Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug. Drug Pipeline Update is delivered to you as a downloadable application, which requires no installation on your computer. Please read more about application features and system requirements below.
Drug Pipeline Update at a Glance
Includes more than 46 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.
Note: You are able to sort and find drugs according to companies and partners from drop-down menus in the application. You may also sort and find drugs according to country of companies.
Drug name & Synonyms
Lists commercial, generic and code names for drugs.
This Drug Pipeline Update contains 122 Fierce 15 drugs in development, which have a total of 326 developmental projects in cancer. In addition there are suspended and ceased drugs.
Pipeline Breakdown According to Number of Drugs
Phase III# 4
Phase II# 25
Phase I# 32
No Data# 3
Note: You are able to sort and find drugs according to developmental stage from drop-down menu in the application.
Included Fierce 15 drugs are also in development for 91 other indications, where of 70 are different cancer indications.
Note: You are able to find and sort drugs according to type of indication from drop-down menu in the application.
All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers. To date 87 out of the 90 studied drug targets so far have been recorded with somatic mutations and the software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.
The identity of available biological structures on 73 drug targets was retrieved from the RCSB Protein Databank for you to easily review the 1073 structures available today among drug targets.
Identified drugs are linked to more than 94 different targets, divided into 37 classifications of molecular function:
- Antigen binding
- ATPase activity
- Auxiliary transport protein activity
- Cell adhesion molecule activity
- Cytokine activity
- DNA binding
- DNA topoisomerase activity
- Extracellular matrix structural constituent
- G-protein coupled receptor activity
- Growth factor activity
- GTPase activity
- Helicase activity
- Kinase activity
- Ligand-dependent nuclear receptor activity
- Ligase activity
- Lipid kinase activity
- Metallopeptidase activity
- Methyltransferase activity
- MHC class I receptor activity
- Molecular function unknown
- Protein binding
- Protein serine/threonine kinase activity
- Protein-tyrosine kinase activity
- Receptor activity
- Receptor binding
- Receptor signaling complex scaffold activity
- Receptor signaling protein serine/threonine kinase activity
- Structural constituent of cytoskeleton
- T cell receptor binding
- Transcription factor activity
- Transcription regulator activity
- Transferase activity
- Translation regulator activity
- Transmembrane receptor activity
- Transmembrane receptor protein tyrosine kinase activity
- Transporter activity
- Ubiquitin-specific protease activity
Identified targets are categorized into 19 different primary and alternate sub-cellular localizations:
- Cell surface
- Clathrin-coated vesicle
- Endoplasmic reticulum
- Extracellular matrix
- Golgi apparatus
- Integral to membrane
- Perinuclear region
- Plasma membrane
Note: You are able to find and sort drugs according to target gene name, protein name, molecular function of target, target localization, presence of mutations and availability of biological structures of target from drop-down menus in the application.
Target Expression Profile
Direct links are provided from inside the application to 128 protein expression profiles of 81 drug targets in various human tissues and cancer types, cell lines and primary cells, including up to:
- 48 different normal tissue types
- 20 different types of cancer
- 47 cell lines
- 12 samples of primary blood cells
Identified targets have been cross referenced against their involvement in different cellular pathways, according to BioCarta, KEGG, NCI-Nature and NetPath.
- BioCarta# 167 Pathways
- KEGG# 146 Pathways
- NCI-Nature# 183 Pathways
- NetPath# 31 Pathways
Note: You are able to find and sort drugs according to targeted pathways from drop-down menus in the application.
In total there are different drug mechanism of action represented in this Drug Pipeline Update.
Note: You are able to find and sort drugs according to mechanism of action from drop-down menu in the application.
Identified drug compounds are described by:
Compound type, Chemical name, CAS Number and molecular weight
Note: You are able to sort and find drugs according to compound type from drop-down menu in the application.
Progress analysis and review of drug development. A typical drug profile reports on, depending on stage of development and available information:
Drug Name & Synonyms
Presentation of drug name and synonyms
Principal Company & Partners
Presentation of principal company and partners
Target and Molecular Function of Target
Described target(s) is/are presented with:
Official Gene Symbol – Chromosome Location – Gene & Protein Name – Molecular Function
Described target(s) is/are presented with primary and alternate localizations.
Target Expression Profiles
Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:
48 different normal tissue types
20 different types of cancer
47 cell lines
12 samples of primary blood cells
All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers.
The identity of available biological structures on drug targets was retrieved from the RCSB Protein Databank for you to easily review what available structures of drug targets exist.
Described target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, NCI-Nature and NetPath.
Drug mechanism of action
Summary field of developmental projects for the drug, including indication, developmental stage and status.
Cancer, myeloma – Phase II Clinical Trial – Active
Cancer, prostate – Phase III Clinical Trial – Ceased
Short introduction to drug
Compound type, Chemical name, CAS Number and molecular weight
Available patent information related to the drug is presented here.
Fillings and Approvals
Approvals and submissions
Deals & Licensing
Collaborations and deals
Availability for licensing
Phase IV Data
Available Phase IV development data, developmental history and scientific data.
Phase III Data
Available Phase III development data, developmental history and scientific data.
Phase II Data
Available Phase II development data, developmental history and scientific data.
Phase I Data
Available Phase I development data, developmental history and scientific data.
Phase 0 Data
Available Phase 0 development data, developmental history and scientific data.
Available preclinical development data, developmental history and scientific data.
Available discovery development data, developmental history and scientific data.
Search, Find and Filter Panel with Initial Result Presentation
With this panel you can define your selectivity in each drug search with up to 24 different drug specific parameters. Each parameter has multi-select options to them and can be used as either an inclusion parameter or exclusion parameter.
The initial result table is a dynamic sortable table which gives you a fast overview of found results and can be narrowed down further by your own additional keywords.
Direct linkage from inside the application to related internet resources
- Drug data is linked to search engines like Google and PubMed
- Drug target data is linked directly to BioCarta, Human Protein Atlas, KEGG, NCI-Nature, NetPath etc.
- Direct links to company web pages of companies
Dynamic Report Generator
Our dynamic report generator lets you with ease and speed generate html reports directly in your web browser (Internet Explorer and FireFox), whether it is a single drug profile or an entire search you want have a report of.
- Operating system: Windows (2000/XP/Vista/7/8) for Mac Users the service is only available online
- Browser Application (Internet Explorer, Firefox, Chrome, Safari)
- Internet access (to access related internet resources)
Read the full report: http://www.reportlinker.com/p02609642-summary/view-report.html
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: [email protected]
Intl: +1 339-368-6001